CompletedNot Applicable

Biomarker and Thrombogenicity Assessment in Cardiopulmonary Bypass Surgery Utilizing Acute Normovolemic Hemodilution

United States43 participantsStarted 2018-03-19

Plain-language summary

This study will help enhance current understanding of the impact of Acute Normovolemic Hemodilution (ANH) administration on transfusion requirements post cardiac surgery, the effect of this procedure on coagulation, and platelet hemostasis, and the amount of chest tube drainage 24 hours post coronary artery bypass graft surgery (CABG) surgery.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. . Subject is 18-85 years old.
✓. . Subject is hemodynamically stable
✓. . The subject is able to read and has signed and dated the informed consent document including Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization permitting release of personal health information as approved by the investigator's Institutional Review Board (IRB).

Exclusion criteria

✕. . Hematocrit \<30 at baseline
✕. . Insufficient (Low) on pump hematocrit of \< 21%
✕. . Patient is hemodynamically unstable
✕. . Patient requiring an emergency procedure
✕. . Left main coronary artery stenosis with evidence of hemodynamic instability (e.g.. hypotension, ST segment elevations on electrocardiogram)
✕. . Aortic valve stenosis with evidence of hemodynamic instability (e.g.. hypotension, ST segment elevations on electrocardiogram)

What they're measuring

Recovery in Platelet Function Post ANH

Timeframe: Baseline through 24 hours post ANH procedure

Trial details

NCT IDNCT03326323

SponsorInova Health Care Services

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-09-17

Results submitted2019-12-06

View on ClinicalTrials.gov More Bleeding Reduction trials